How to buy Five Prime Therapeutics stock - 10 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Five Prime Therapeutics stock

Own Five Prime Therapeutics stock in just a few minutes.

Five Prime Therapeutics, Inc is a biotechnology business based in the US. Five Prime Therapeutics shares (FPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Five Prime Therapeutics employs 51 staff and has a trailing 12-month revenue of around USD$13.2 million.

How to buy shares in Five Prime Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Five Prime Therapeutics. Find the stock by name or ticker symbol: FPRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Five Prime Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Five Prime Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Five Prime Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Five Prime Therapeutics share price

Use our graph to track the performance of FPRX stocks over time.

Five Prime Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$2.61 - USD$38.9
50-day moving average USD$33.0974
200-day moving average USD$18.3107
Wall St. target priceUSD$37.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.486

Buy Five Prime Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Five Prime Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Five Prime Therapeutics under- or over-valued?

Valuing Five Prime Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Five Prime Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Five Prime Therapeutics's PEG ratio

Five Prime Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Five Prime Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Five Prime Therapeutics financials

Revenue TTM USD$13.2 million
Gross profit TTM USD$-43,243,000
Return on assets TTM -17.19%
Return on equity TTM -40.58%
Profit margin 0%
Book value $5.782
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting Five Prime Therapeutics shares

There are currently 1.9 million Five Prime Therapeutics shares held short by investors – that's known as Five Prime Therapeutics's "short interest". This figure is 33.1% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting Five Prime Therapeutics shares can be evaluated.

Five Prime Therapeutics's "short interest ratio" (SIR)

Five Prime Therapeutics's "short interest ratio" (SIR) is the quantity of Five Prime Therapeutics shares currently shorted divided by the average quantity of Five Prime Therapeutics shares traded daily (recently around 4.0 million). Five Prime Therapeutics's SIR currently stands at 0.48. In other words for every 100,000 Five Prime Therapeutics shares traded daily on the market, roughly 480 shares are currently held short.

However Five Prime Therapeutics's short interest can also be evaluated against the total number of Five Prime Therapeutics shares, or, against the total number of tradable Five Prime Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Five Prime Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Five Prime Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.048% of the tradable shares (for every 100,000 tradable Five Prime Therapeutics shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Five Prime Therapeutics.

Find out more about how you can short Five Prime Therapeutics stock.

Five Prime Therapeutics share dividends

We're not expecting Five Prime Therapeutics to pay a dividend over the next 12 months.

Five Prime Therapeutics share price volatility

Over the last 12 months, Five Prime Therapeutics's shares have ranged in value from as little as $2.61 up to $38.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Five Prime Therapeutics's is 4.6271. This would suggest that Five Prime Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Five Prime Therapeutics overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site